Conference 2018 - 'What future, the PBS?'May 14, 2018 Level 3, Establishment hotel 252 George Street, Sydney
Registration for the PharmaDispatch conference 2018 is now open
The one-day event will be held at the Establishment hotel in Sydney (level 3), on Monday 14 May, with the theme is - What future, the PBS?
The event venue opens at 8am on Monday 14 May and closes with a reception ending at 7pm.
The first panel, starting at 8.30am, features a panel discussion on the future of the PBS with PBAC chair Professor Andrew Wilson, Hepatitis Australia president and former senior Department of Health official Felicity McNeill PSM, the managing director of Novo Nordisk and Medicines Australia board member Michala Fischer-Hansen, and PBAC consumer representative and deputy chair of the Consumers Health Forum, Jo Watson.
Former Department of Finance secretary, Jane Halton AO PSM, who also spent over a decade as secretary of the Department of Health, will speak at the conference.
Chair of Medicines Australia and Boehringer Ingelheim managing director, Wes Cook, will participate in the conference, as will Guild national president, George Tambassis, and Mark Hooper, CEO of Sigma Healthcare and chair of the National Pharmaceutical Services Association. Allan Tillack, chair of the Generic and Biosimilar Medicines Association and managing director of Sandoz, will also participate.
The leaders panel is designed to discuss how the sector will come together to make the case for more investment in the PBS.
A panel of managing directors, featuring Takeda’s James Jones and AstraZeneca’s Liz Chatwin, will focus on the future of the PBS from a company perspective.
Industry nominated PBAC member, Michelle Burke, who is also on the board of AusBiotech, will provide her perspective as a member of the committee. Ms Burke will be joined on a panel by David Herd, director of market access and external affairs at GSK, as well one other senior market access executive.
Other panels will seek to shed light on the complexity of deeds of agreement and rebates, the supply chain, the changing face of government and stakeholder relations, and the challenges posed by the PBS for the sector’s commercial leaders.
Confirmed speakers include Belinda Wood, CEO of the Generic and Biosimilar Medicines Association, Richard Vines of Rare Cancers Australia, patient and advocate Jessica Bean, pharmacy and supply chain expert Bruce Annabel, Liz de Somer from Medicines Australia, MSD's Nicola Richards, AstraZeneca’s Kieran Schneemann, Janssen’s Todd Stephenson and Jody Fassina from Insight Strategy.
A number of other speakers have been invited. They will be confirmed in the weeks ahead.
Catering will be provided and registrants are asked to advise on any dietary requirements.
Registrations are limited with a number of heavily discounted spots set aside for patient representative groups. Full individual registration for the conference is $880 (GST incl.). Patient representative groups or anyone with questions should contact us (firstname.lastname@example.org) for further information.Register Now